** Shares of oncology-focused biotech firm Ideaya Biosciences rise 14.4% to $39.17
** Co announced positive results from a mid-stage study testing a higher dose of its experimental cancer drug in pre-treated patients with a type of bladder and lung cancer
** Co says the drug called IDE397 showed an overall response rate of 39%, the proportion of patients whose cancers disappeared or shrank
** Adds, 14 out of 18 patients observed tumor shrinkage
** Co says there were no drug related serious adverse events observed
** Says IDE397 expansion dose of 30 mg once-a-day achieved target drug coverage
** Including session moves, stock up 9.2% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Comments